Results 161 to 170 of about 4,694,538 (359)

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

open access: yesMolecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald   +18 more
wiley   +1 more source

Evaluating Extension Programs

open access: yesEDIS, 2011
Is program evaluation just a “necessary evil” for Extension program implementation? Or, rather, an opportunity to identify and document accomplishments and discover ways to strengthen the impact of programs? This 5-page fact sheet defines evaluation, explains why evaluation is important to Extension programming beyond accountability requirements ...
Alexa J. Lamm   +3 more
openaire   +3 more sources

Dynamic Evaluation of Job Search Assistance [PDF]

open access: yes
This paper evaluates a job search assistance program for unemployment insurance recipients. The assignment to the program is dynamic. We provide a discussion on dynamic treatment effects and identification conditions.
Kastoryano, Stephen, van der Klaauw, Bas
core  

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias   +12 more
wiley   +1 more source

Centers for Disease Control and Prevention Harvard Program Evaluation Practicum: 10 Years of Partnership in Public Health Program Evaluation. [PDF]

open access: yesJ Womens Health (Larchmt), 2023
Ramsey LM   +8 more
europepmc   +1 more source

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

open access: yesMolecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche   +8 more
wiley   +1 more source

Framework for the cost benefit analysis of the NSW Department of Community Services Brighter Futures Program. CHERE Working Paper 2009/4. [PDF]

open access: yes
Brighter Futures is the NSW DOCS early intervention program targeting children aged 0 to 8. The program is designed to ?support pregnant women and families with young children aged 0-8 years who require long-term support (up to two years) by a range of ...
Gisselle Gallego   +4 more
core  

Home - About - Disclaimer - Privacy